Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 6;13:5886. doi: 10.1038/s41467-022-33309-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a–g Efficacy of DMAb cocktails (TM or WT) compared to the rIgG cocktail (WT) benchmark in mice. a Schematic of lethal challenge in 6–8-week-old female K-18 mice (n = 12 independent biological replicates). b Individual serum antibody levels (group GM (±GSD) indicated) following plasmid or rIgG administration (n = 12). c–e Measurements of viral control in individual animals (TCID50/g tissue) at D4. Viral loads (group GM (±GSD) indicated) in the c NT and d lung were compared using a Kruskal–Wallis test followed by Dunn’s post hoc analysis. P values indicated. Horizontal lines indicate LOD. e Histopathology scores for individual H&E-stained lung sections (group averages (±SD) shown). e, f Challenge outcome in individual animal (n = 8 or 7 (WT(m3) DMAb group) independent biological replicates). f Body weight change (%) and g Survival (%) were monitored. Survival curves were compared using a Mantel–Cox Log-rank test. P value indicated. h–n Efficacy of DMAb cocktails (TM or WT) in a SARS-CoV-2 hamster challenge model. h Schematic of non-lethal challenge conducted in 7–8-week-old female Syrian golden hamsters (n = 6 biological replicates). i Pre-challenge serum DMAb levels in individual hamsters (group GM (±GSD) shown). j Antiviral activity of individual hamster sera (pre-challenge) against live SARS-CoV-2 (USA-WA1/2020). ID50 values (group GM (±GSD)) are displayed. k–m Measurements of viral control (TCID50/g tissue) at D4 post-challenge in the k lung and l NT of individual animals (group GM (±GSD) indicated). Groups were compared using a Kruskal–Wallis test followed by Dunn’s post hoc analysis. P values indicated. Horizontal lines indicate LOD. m Cumulative lung histopathology score for each animal (group means (±SD) indicated). Lung sections were scored for microscopic indications of edema, hemorrhage, hyperplasia, hypertrophy, metaplasia, mineralization and syncytial cells. Group scores were compared using a Kruskal–Wallis test followed by Dunn’s post hoc analysis. P values. n Body weight change (%) for each animal following challenge. Source data are provided as a Source Data file.